Overview of the DESTINY-Breast06 Study

Panelists discuss the results and implications of the DESTINY-Breast06 study, highlighting the efficacy of trastuzumab deruxtecan in patients with HER2-positive breast cancer previously treated with multiple lines of therapy.

Now Viewing

EP: 1.Overview of the DESTINY-Breast06 Study

EP: 2.Overview of the DESTINY-Breast12 Study

EP: 3.Overview of the PATINA Study

Recent Videos